Annual Report FY 2025-26 filed; 41st AGM notice included

Results View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.2%Reaction day

₹1076.00

prior close

₹1097.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.3%-0.2% vs market

Pharmaceuticals peers, median of 164sector+1.0%+0.2% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

-0.8

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.2+1.3-0.2+1.0+0.2

Next day

+1.4+1.8-0.3+0.7+0.7

+7.4+3.1+4.3+0.3+7.2

+5.8+3.5+2.4+0.7+5.1

-0.9+3.5-4.4+1.4-2.3

-1.3+3.4-4.7+1.2-2.5

-0.7+3.6-4.3+1.6-2.3

15d

—+4.9—+0.9—

—+4.4—+1.6—

—+2.9—+1.7—

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Jenburkt Pharmaceuticals has submitted its Annual Report for FY 2025-26 to BSE. The filing includes audited standalone financial statements, the auditor's report, the directors' report, and the notice convening the 41st Annual General Meeting. Shareholders can now review the full-year financial performance and governance disclosures ahead of the AGM.

Likely market impact

Routine regulatory filing. Investors should review the annual report for full-year financials and AGM agenda items before the meeting.